CY1113115T1 - Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties - Google Patents

Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties

Info

Publication number
CY1113115T1
CY1113115T1 CY20121100268T CY121100268T CY1113115T1 CY 1113115 T1 CY1113115 T1 CY 1113115T1 CY 20121100268 T CY20121100268 T CY 20121100268T CY 121100268 T CY121100268 T CY 121100268T CY 1113115 T1 CY1113115 T1 CY 1113115T1
Authority
CY
Cyprus
Prior art keywords
seq
hiv fusion
peptides
biological properties
fusion inhibitors
Prior art date
Application number
CY20121100268T
Other languages
Greek (el)
Inventor
John Dwyer
Brian L Bray
Stephen E Schneider
Huyi Zhang
Nicolai A Tvermoes
Barbara E Johnston
Paul E Friedrich
Original Assignee
Synageva Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp. filed Critical Synageva Biopharma Corp.
Publication of CY1113115T1 publication Critical patent/CY1113115T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Παρέχεται ένα πεπτίδιο αναστολέας σύντηξης του ΗIV που έχει μία αλληλουχία αμινοξέος οποιασδήποτε από τις SEQ ID Νο:9, SEQ ID Νο:10, SEQ ID Νο:11, SEQ ID Νο:12, SEQ ID Νο:13, SEQ ID Νο:14 ή SEQ ID Νο:15· και παρέχεται μία φαρμακευτική σύνθεση που περιλαμβάνει ένα πεπτίδιο αναστολέα σύντηξης του ΗIV και έναν, ή περισσότερους από έναν, φαρμακευτικώς αποδεκτό φορέα και ένα μακρομοριακό φορέα, και χρήσεις και μέθοδοι θεραπείας που παρέχονται από αυτές τις συνθέσεις.An HIV fusion inhibitor peptide having an amino acid sequence of any of SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14 or SEQ ID No. 15; and there is provided a pharmaceutical composition comprising an HIV fusion inhibitor peptide and a, or more than one, pharmaceutically acceptable carrier and a macromolecular carrier, and uses and methods of treatment provided by these compositions.

CY20121100268T 2006-02-02 2012-03-14 Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties CY1113115T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76467406P 2006-02-02 2006-02-02
EP07749903A EP1989220B1 (en) 2006-02-02 2007-02-02 Hiv fusion inhibitor peptides with improved biological properties

Publications (1)

Publication Number Publication Date
CY1113115T1 true CY1113115T1 (en) 2016-04-13

Family

ID=38437849

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100268T CY1113115T1 (en) 2006-02-02 2012-03-14 Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties

Country Status (15)

Country Link
US (3) US7456251B2 (en)
EP (1) EP1989220B1 (en)
JP (1) JP4682251B2 (en)
CN (1) CN101415723B (en)
AR (2) AR059300A1 (en)
AT (1) ATE537183T1 (en)
AU (1) AU2007218025A1 (en)
CA (1) CA2651793C (en)
CY (1) CY1113115T1 (en)
DK (1) DK1989220T3 (en)
ES (1) ES2381631T3 (en)
NZ (1) NZ570300A (en)
PT (1) PT1989220E (en)
TW (1) TWI341844B (en)
WO (1) WO2007097903A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097903A2 (en) 2006-02-02 2007-08-30 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
MX2010003179A (en) * 2007-09-25 2010-04-30 Trimeris Inc Methods of synthesis for therapeuthic anti-hiv peptides.
US8828931B2 (en) * 2008-05-28 2014-09-09 New York Blood Center, Inc. Bifunctional molecules for inhibiting HIV entry
EP2377880A3 (en) * 2008-08-13 2012-03-21 New York Blood Center Combination therapy of HIV fusion entry inhibitors targeting gp41
WO2010045613A1 (en) * 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric hiv vaccines
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
US9115186B2 (en) * 2009-02-09 2015-08-25 New York Blood Center Stabilized trimeric HIV-1 gp41 fusion polypeptides comprising the N-terminal heptad repeat (NHR) and foldon (FD) trimerization motif
CA2794632A1 (en) 2010-05-03 2011-11-10 New York Blood Center, Inc. Bifunctional molecules for inactivating hiv and blocking hiv entry
JP2015502378A (en) * 2011-12-19 2015-01-22 ヤンセン・アールアンドデイ・アイルランド HIV membrane fusion inhibitor
EP2834264A1 (en) 2012-04-04 2015-02-11 Yeda Research and Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN103724404B (en) * 2013-12-08 2016-11-02 北京工业大学 Diastereomer polypeptide that suppression inhibition of HIV merges with host cell and application thereof
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN109320593A (en) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 Inhibit the helical polypeptide and application thereof of HIV infection

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
CN1030256A (en) * 1987-06-29 1989-01-11 日清食品株式会社 Detect and treat method and the material of human immunodeficiency virus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1993007603A1 (en) 1991-10-04 1993-04-15 Cornett Robert H Approaching emergency vehicle warning system
WO1994002505A1 (en) 1992-07-20 1994-02-03 Duke University Compounds which inhibit hiv replication
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
JP3698721B2 (en) 1993-02-23 2005-09-21 ジェネンテク・インコーポレイテッド Excipient stabilization of polypeptides treated with organic solvents
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
WO1996040191A1 (en) 1995-06-07 1996-12-19 Trimeris, Inc. The treatment of hiv and other viral infections using combinatory therapy
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
AU742250B2 (en) 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
JPH11209456A (en) * 1998-01-29 1999-08-03 Hitachi Chem Co Ltd Flame-retardant epoxy resin composition for printed circuit board, and prepreg and metal-clad laminate prepared therefrom
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
ATE443714T1 (en) 1999-05-17 2009-10-15 Conjuchem Biotechnologies Inc LONG-ACTING PEPTIDE INHIBITORS OF VIRUS FUSION WITH BODY CELLS IN VIRAL INFECTIONS
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
JP4361710B2 (en) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド Sustained release formulation
AU2002320122B2 (en) 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
CN1100564C (en) 2001-08-29 2003-02-05 周根发 Medicine for treating HIV infection, its composition and its use
US7045552B2 (en) 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
EP1708734A4 (en) * 2004-01-07 2009-06-17 Trimeris Inc HIV gp41 HR2-DERIVED SYNTHETIC PEPTIDES, AND THEIR USE IN THERAPY TO INHIBIT TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS
CA2556032A1 (en) * 2004-03-15 2005-09-29 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides
CN101132812A (en) 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Polymer-based compositions and conjuates of HIV entry inhibitors
WO2007097903A2 (en) 2006-02-02 2007-08-30 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties

Also Published As

Publication number Publication date
CN101415723A (en) 2009-04-22
US8034899B2 (en) 2011-10-11
US20070179278A1 (en) 2007-08-02
EP1989220B1 (en) 2011-12-14
US20120040891A1 (en) 2012-02-16
ES2381631T3 (en) 2012-05-30
ATE537183T1 (en) 2011-12-15
PT1989220E (en) 2012-03-23
TW200806687A (en) 2008-02-01
US20090105143A1 (en) 2009-04-23
DK1989220T3 (en) 2012-04-02
TWI341844B (en) 2011-05-11
WO2007097903A3 (en) 2008-05-22
WO2007097903A2 (en) 2007-08-30
JP4682251B2 (en) 2011-05-11
JP2009525051A (en) 2009-07-09
EP1989220A4 (en) 2009-05-06
CA2651793A1 (en) 2007-08-30
CA2651793C (en) 2015-07-07
AR059300A1 (en) 2008-03-26
US7456251B2 (en) 2008-11-25
CN101415723B (en) 2014-06-25
NZ570300A (en) 2011-08-26
EP1989220A2 (en) 2008-11-12
AU2007218025A1 (en) 2007-08-30
AR108277A2 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
CY1113115T1 (en) Peptides - HIV Fusion Inhibitors with Enhanced Biological Properties
CY1121125T1 (en) COMPOSITIONS FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION
RS53236B (en) Peptides for treating beta-amyloidoses
MX2009005881A (en) Non-nucleoside reverse transcriptase inhibitors.
CY1118731T1 (en) ALVIGLUTIDIS PHARMACEUTICAL COMPOSITIONS
CY1115289T1 (en) Methods of Treatment Against Inflammation-Related Illness
CY1117995T1 (en) SECONDARY PRODUCTS OF CATEGOLAMIN AND MEDICINES CONTAINING THE THESE COMPOUNDS
CY1113379T1 (en) KDR Peptides and Vaccines Included
EA200802170A1 (en) LYOPHILIZED COMPOSITION OF THERAPEUTIC PEPTIDE ANTIBODY
PE20161325A1 (en) L-ASPARAGINASE TREATED WITH PEG
RU2013126581A (en) STREPTokinase MUTANTS AND THEIR COVALENT MODIFIED FORMS
AR076349A1 (en) CANCER ANTIGEN AUXILIARY PEPTIDE
BRPI0509074A (en) pharmaceutical compositions comprising thyroid receptor agonists
CY1111613T1 (en) METHODS FOR TREATMENT OF HIV INFECTION
EA200900184A1 (en) 4-AMINO-4-OXOBUTANOYL PEPTIDES AS VIRAL REPLICATION INHIBITORS
RS52537B (en) Activin-actrii antagonists and uses for treating anemia
CO6241137A2 (en) CXCR4 CYCLE PEPTIDE ANTAGONISTS
EA200900064A1 (en) INHIBITION OF ALPHA-SINUCLEIN AGGREGATION
DK1948155T3 (en) Pharmaceutical compositions comprising droxidopa
NZ607892A (en) Tfpi inhibitors and methods of use
BRPI0408353A (en) compound, pharmaceutical composition, methods for the treatment of susceptible neoplasms and for the treatment of viral infections, and, use of a compound
CY1112992T1 (en) MEDICINE WITHOUT CONDITION FOR THE PREPARATION OF RECONCILIATED GONODOTROPINS
UA100127C2 (en) Peptide cdh3 and drug containing it
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
ES2530670T3 (en) Anti-FGF23 antibody and pharmaceutical composition comprising the same